CDER’s latest proposal to withdraw the accelerated approval of Makena (HPC) was centered on a sizable randomized trial that failed to confirm the good thing about this drug to newborns or lessen the potential risk of PTB. In earning the decision to propose Makena’s withdrawal, CDER also reviewed effects from prior studies of progestins (HPC a